Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Joachim Stangier, PhD, Bengt I Eriksson, MD, Michael H Huo, MD, Richard J Friedman, MD, Ola E Dahl, MD, Martin Feuring, MD

Blood (2011) 118 (21): 2307.

https://doi.org/10.1182/blood.V118.21.2307.2307

Published: 2011

Journal Articles

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Bengt I Eriksson, MD, John J Smith, MD, PhD, Joseph Caprini, MD, Stefan Hantel, PhD, Andreas Clemens, MD, Martin Feuring, MD, Gregory W Barsness, MD

Blood (2011) 118 (21): 2309.

https://doi.org/10.1182/blood.V118.21.2309.2309

Published: 2011

Journal Articles

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Michael H Huo, MD, Andreas A Kurth, MD, Ola E Dahl, MD, Andreas Clemens, MD, Stefan Hantel, PhD, Martin Feuring, MD, Richard J Friedman, MD, Bengt I Eriksson, MD, PhD

Blood (2011) 118 (21): 2312.

https://doi.org/10.1182/blood.V118.21.2312.2312

Published: 2011

Journal Articles

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Ola E Dahl, Andreas A Kurth, Nadia Rosencher, Janet Schnee, Andreas Clemens, Herbert Noack, Bengt I Eriksson

Blood (2008) 112 (11): 437.

https://doi.org/10.1182/blood.V112.11.437.437

Published: 2008

Journal Articles

Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.

Ola E Dahl, Andreas A Kurth, Nadia Rosencher, Janet Schnee, Andreas Clemens, Herbert Noack, Bengt I Eriksson

Blood (2008) 112 (11): 981.

https://doi.org/10.1182/blood.V112.11.981.981

Published: 2008

Journal Articles

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Richard J. Friedman, MD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Tiemo J. Bandel, MD, Eva Muehlhofer, MD, Frank Misselwitz, MD, William Geerts, MD

Blood (2007) 110 (11): 6.

https://doi.org/10.1182/blood.V110.11.6.6

Published: 2007

Journal Articles

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Bengt I. Eriksson, MD, PhD, Alexander G.G. Turpie, MD, PhD, Michael R. Lassen, MD, PhD, Martin H. Prins, MD, PhD, Giancarlo Agnelli, MD, PhD, Peter Kälebo, MD, PhD, Graham Wetherill, MSc, Lambertus Meems, MSc.

Blood (2007) 110 (11): 309.

https://doi.org/10.1182/blood.V110.11.309.309

Published: 2007

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

Journal Articles

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Bengt I. Eriksson, MD, PhD, Ola E. Dahl, MD,PhD, Cornelis N. van Dijk, MD,PhD, Simon P. Frostick, MA,DM,FRCS, Andreas A. Kurth, MD,PhD, Nadia Rosencher, MD, Janet Schnee, MD, Rohan Hettiarachchi, MD,PhD, Anita V. Christiansen, MSc.Pharm., Stefan Hantel, PhD, Harry R. Büller, MD,PhD

Blood (2006) 108 (11): 573.

https://doi.org/10.1182/blood.V108.11.573.573

Published: 2006

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

Theodore E. Warkentin, Richard J. Cook, Victor J. Marder, Jo-Ann I. Sheppard, Jane C. Moore, Bengt I. Eriksson, Andreas Greinacher, John G. Kelton

Blood (2005) 106 (12): 3791–3796.

https://doi.org/10.1182/blood-2005-05-1938

Published: 2005

Journal Articles

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Sebastian M. Schellong, MD, Jan Beyer, MD, Kai Halbritter, MD, Benjamin Schmidt, MD, Alexander G.G. Turpie, MD, Bengt I. Eriksson, MD, PhD, Frank Misselwitz, MD, PhD, Peter Kälebo, MD

Blood (2005) 106 (11): 281.

https://doi.org/10.1182/blood.V106.11.281.281

Published: 2005

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

Journal Articles

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Bengt I. Eriksson, MD, Alexander G.G. Turpie, MD, Michael R. Lassen, MD, Martin H. Prins, MD, Giancarlo Agnelli, MD, Marleen L. Gaillard, PhD, Bert Meems, MSc

Blood (2005) 106 (11): 1865.

https://doi.org/10.1182/blood.V106.11.1865.1865

Published: 2005

Journal Articles

Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance

Andreas Greinacher, Petra Eichler, Dorothea Albrecht, Ulrike Strobel, Bernd Pötzsch, Bengt I. Eriksson

Blood (2003) 101 (7): 2617–2619.

https://doi.org/10.1182/blood-2002-04-1055

Published: 2003

NARROW

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only